1-(3-苯氧基丙基)咪唑 | 62838-60-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3-苯氧基丙基)咪唑
• 英文名称: 1-(3-phenoxypropyl)-1H-imidazole
• 英文别名: N-(3-Phenoxypropyl)imidazol；1-(3-Phenoxypropyl)imidazole
• CAS: 62838-60-2
• 化学式: C₁₂H₁₄N₂O
• mdl: MFCD00977731
• 分子量: 202.256
• InChiKey: SZQUYCHMYGBJGI-UHFFFAOYSA-N

物化性质

• 溶解度：
  25.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯酚 在 四丁基溴化铵 、 potassium carbonate 、 三乙胺 作用下， 以 丙酮 、 乙腈 为溶剂， 90.0~100.0 ℃ 、1.03 MPa 条件下， 反应 45.5h， 生成 1-(3-苯氧基丙基)咪唑
  参考文献：
  名称：

  Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties

  摘要：

  A novel series of aryloxyalkyl derivatives of imidazole and 1,2,4-triazole, 17-31, was designed and synthesized as inhibitors of heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Some of these compounds were found to be good inhibitors of HO-1, in particular those carrying an imidazole moiety as azolyl group and a 3-bromo or 4-iodophenyl as aryl moiety. The most potent compounds 6 and 30 were selected and studied for their antitumor properties in a model of LAMA-84 R cell line overexpressing HO-1 and resistant to imatinib mesylate (IM), a tyrosine-kinase inhibitor used in the treatment of multiple types of cancer, most notably Philadelphia Chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML). Results show that both 6 and 30 sensitized LAMA-84 R cell line to antitumor properties of IM. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.040

文献信息

• Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
  申请人：Gupta Ajay

  公开号：US20110319459A1

  公开（公告）日：2011-12-29

  Disclosed are compounds of the general formula (I): TC n D  (I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

  本发明涉及一般式（I）的化合物：TCnD（I），包括单独使用或与其他化疗药物联合使用的有效量的该化合物的组合物，以及用于治疗或预防癌症和抑制肿瘤组织生长的有用方法。这些化合物减弱了与增加血红素氧合酶活性相关的氧化损伤，并可以减少转化细胞中的细胞增殖。此外，所述化合物和组合物可用作神经保护剂，并用于治疗或预防中枢神经系统的神经退行性疾病和其他疾病。
• PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS
  申请人：BERDINI Valerio

  公开号：US20130005702A1

  公开（公告）日：2013-01-03

  The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

  本发明提供了公式(I)的化合物，具有蛋白激酶B抑制活性。还提供了含有该化合物的制药组合物，制备该化合物的方法以及其作为抗癌剂的用途。
• 1-[(Aryloxy)alkyl]-1<I>H</I>-imidazoles as Inhibitors of Neuronal Nitric Oxide Synthase
  作者：L. Salerno、V. Sorrenti、F. Guerrera、M.C. Sarvà、M.A. Siracusa、C. Di Giacomo、A. Vanella

  DOI：10.1211/146080899128735225

  日期：1999.8.1
• US20140271662A1
  申请人：——

  公开号：US20140271662A1

  公开（公告）日：2014-09-18
• US8691806B2
  申请人：——

  公开号：US8691806B2

  公开（公告）日：2014-04-08